PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5
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The PAX5 gene encodes for a transcription factor essential for B-cell development, 1,2 which has been recently reported as frequent target of aberrancies, including mutations, deletions and translocations in B30% of pediatric patients with B-cell precursor acute lymphoblastic leukemia. 3, 4 Among several translocations with different partner genes, the t(9;12) encoding for the PAX5/ETV6 fusion, is the most recurrent. 2 The role of PAX5/ETV6 in leukemogenesis is not fully understood, although preliminary evidences suggested that the protein may have a repressor function on transcription. 3, 5, 6 The PAX5/ETV6 protein retains the ability to interact with the PAX5-consensus sequence contained in the CD19 promoter, 6 and it is able to multimerize and bind the PAX5-consensus sequence with high affinity, determining a dominant negative activity on wt PAX5. 7 Herein, we explored the effect of PAX5/ETV6 on the transcription in precursor B cells and whether the fusion gene specifically affects the PAX5 and ETV6 physiological pathways. We performed a genome-wide expression analysis in murine wild-type cKIT þ B220 þ CD19 þ pre-BI cells 8 transduced by the retroviral MIGR-PAX5/ETV6 vector, as previously described. 5 We used three different cell populations, called LY5.1FL, FLB6-67 and B6BAFL cells, respectively, isolated from fetal liver of diverse mouse strain donors.
The gene expression profile (GEP) was obtained in two independent experiments on B6BAFL pre-BI cells, whereas the validation experiments were carried out in all the three cell populations. Here we present the main findings, while more detailed information are reported in the Supplementary Information.
Statistical analysis selected 340 differentially expressed genes (DEGs) over 12 761 probe sets, which defined a PAX5/ETV6-specific signature (Figure 1a ; Supplementary Table S1 ). By setting the fold change (FC) as FCX1.5 or p0.7, we observed 245 out of 340 (72%) downregulated genes, whereas 28% (n ¼ 95/340) were upregulated, thus suggesting that PAX5/ETV6 acts mainly, but not exclusively, as a transcriptional repressor. The expression of 49 transcripts, including 28 downregulated and 21 upregulated genes, was successfully validated by RQ-PCR (Supplementary Tables S2  and S3 ). The downregulation of genes was further confirmed at the protein level. Indeed, by protein arrays, tumor necrosis factor alpha (TNFa) was decreased of 80% (t-test, P ¼ 0.0079) in B6BAFL cells (Figure 1a) , consistent with reduced TNFa transcript (FC ¼ 0.46 in GEP). Interestingly, two additional genes from the TNF family, lymphotoxin A (LTA) and lymphotoxin B (LTB), were strongly repressed by PAX5/ETV6 (Supplementary Table S2 ). Moreover, we validated by RQ-PCR and FACS analyses the reduction of CD19 and three cell surface PAX5 targets, namely CD22, SLAMF6/LY108 and CD44 antigens (Supplementary Figures S1-S3) .
A consistent number of DEGs (n ¼ 34/340, 10%) are annotated to be direct transcriptional targets of PAX5 (refs 9-12) Table S1 and Supplementary Methods). Indeed, the noteworthy P-value confirms that PAX5/ ETV6 especially affects the PAX5 transcriptional pathway.
In particular, for the first time, we observed that PAX5/ETV6 exerts a dual regulation on wt PAX5 transcription function, by repressing 56% (19/34) and activating 44% (15/34) of PAX5-target genes, respectively (Supplementary Figure S4) . In addition, about 63% (12/19) of PAX5-target genes repressed by PAX5/ETV6 are known to be normally activated by wt PAX5, whereas only 37% (7/19) are physiologically repressed by wt PAX5. Similarly, 73% (11/15) of PAX5/ETV6 upregulated genes, are known to be PAX5 repressed and only 27% (4/15) are activated also by wt PAX5. Comprehensively, PAX5/ETV6 modulated 68% of PAX5-target genes in an opposite direction to wt PAX5, whereas PAX5/ETV6 and PAX5 activity is concordant only on 32% of targets (Supplementary Figure S4) .
A canonical dominant negative effect of several PAX5 fusions over wt PAX5 was previously proposed, through the mechanism of DNA-binding competition. 2 Differently, we herewith propose
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Letters to the Editor that PAX5/ETV6 has a more complex role on wt PAX5, defined here as an opposite dominant function (Supplementary Figure S5) . Furthermore, by setting a less stringent threshold (FCp0.90), we recognized the presence of 52 additional PAX5-target probes (Supplementary Table S4 ), giving a total of 71 genes repressed by PAX5/ETV6, the majority of them being activated by wt PAX5 (n ¼ 46/71, 65%). Similarly, by setting a less stringent threshold (FCX1.10) we recognized 46 additional PAX5-target genes (Supplementary Table S4 ), for a total of 61 physiological PAX5-target genes activated by PAX5/ETV6, 34 among them (56%) being known as to be PAX5 repressed.
Among genes repressed by wt PAX5 but upregulated by PAX5/ ETV6 is the H19 gene, which is the immature precursor of mir-675-5p and mir-675-3p. 13 By RQ-PCR assay, we confirmed that H19 (Supplementary Table S3 We additionally investigated the expression of PAX5/ETV6-activated but wt PAX5-repressed genes in PAX5
À / À pro-B cells. Although in the absence of wt PAX5, PAX5-repressed genes are (obviously) already activated in these cells, PAX5/ETV6 induces a further increase of RAMP1A, TSPAN, LCK and H19 levels. H19 has FC ¼ 1.67 (P ¼ 0.0302 by t-test), and accordingly mir-675-3p and5p increased hundreds time (FC ¼ 373.44; P ¼ 0.0085 by t-test, and FC ¼ 24.41; P ¼ 0.0001 by t-test, respectively) ( Supplementary  Figures S6E and F) .
On the other hand, only a few ETV6 transcriptional target genes 14 were differentially expressed and validated (Ldlr and Cirbp, n ¼ 2/340, 0.6%), even considering the less stringent threshold (Supplementary Tables S1, S2 and S5) . Therefore, it was not possible to assess whether the fusion protein had a role in the ETV6 pathway.
Certainly, GEP data suggested an opposite dominant interference of the PAX5/ETV6 protein on the wt PAX5 transcription pathway, which could be exerted through a direct competition between PAX5 and PAX5/ETV6, although we cannot exclude alternative mechanisms that need to be experimentally explored. Indeed, PAX5 repression was observed at mRNA level (Supplementary Figure S7A) . Moreover, by western blot analysis using an anti-N-term PAX5, we observed a significant reduction of the endogenous PAX5 in PAX5/ETV6 cells, even though wt pre-BI cells have two wt PAX5 alleles (Figure 1b) . The PAX5 reduction was confirmed (Supplementary Figure S7B) by using a wt PAX5-specific anti C-terminus antibody, with a À 47% mean decrease in LY5.1FL, À 34% in FLB6-67 and À 35% in B6BAFL (details in Supplementary Results). Although we cannot prove here whether PAX5/ETV6 directly regulates PAX5 protein, its downregulation may be a potentially important mechanism in transformation: indeed, in human leukemia, one PAX5 allele is involved in the translocation event, and the second wt PAX5 allele could be partially repressed plus partially hindered by the fusion protein in its function.
To establish the comprehensive functional significance of the PAX5/ETV6 transcription profile, even in the presence of relatively small changes in gene expression, IPA and DAVID pathway analysis software, applied on the DEGs list, consistently identified genes involved in B-cell receptor signaling and adhesion processes (Supplementary Bioinformatics file). The downregulation was further confirmed for additional PAX5-activated genes known to be involved in pre-BCR signaling but not present in the microarray, as described in Supplementary Results and Supplementary Table S6 . To functionally prove whether the assembly and signaling of pre-BCR was impaired, we stimulated IgM rearrangement by culturing LY5.1FL cells in the presence of sub-optimal levels of IL-7 (0.5%). By FACS, we analyzed m-chain expression on cell surface, and representative phenotypes are reported (Figure 1c) . At day 0, we detected no protein expression on control or PAX5/ETV6 cells (1.22 and 0.28% m-positive cells, respectively). At day þ 5, control cells expressed remarkable levels of m chain (40.84% m-positive cells) as compared with PAX5/ETV6 cells (2.82%), which indeed exhibited a severe defect in pre-BCR assembly.
In parallel, we demonstrated a modulation of genes responsible for extracellular binding as well as involved in the intracellular signaling, supporting the role of PAX5/ETV6 in adhesion (Supplementary Results and Supplementary Table S7 ). In particular, we focused the attention on VCAM1, a VLA4-binding B-cell adhesion molecule in bone marrow, 12 which is composed by integrins CD29 and CD49d. Both were expressed at comparable levels on PAX5/ETV6 and control cells (Supplementary Figure S8) . In an in vitro adhesion assay to VCAM1, PAX5/ETV6 cells turned out to have a significant reduction of adhesion rate in basal conditions (Figure 2a ) (LY5.1FL: À 51%, P ¼ 0.0556; FLB6-67 cells: À 39%, P ¼ 0.0027; B6BAFL cells: À 67%, P ¼ 0.0230). In presence of the CXCL12 chemokine (Figure 2b ), which represents a positive signal to VCAM1-mediated adhesion and to migration, PAX5/ETV6 cells efficiently responded to the stimulus by improving their adhesion rate, but the overall response was lower than control cells in LY5.1FL ( À 55%, P ¼ 0.0418;) and in FLB6-67 ( À 41%, P ¼ 0.0178), whereas B6BAFL cells showed the same response rate. In addition to the previously reported increased migration rate, 5 reduced adhesion could lead to tissues infiltration, although in vivo experiments are necessary to prove this.
In conclusion, the opposite dominance of PAX5/ETV6 over endogenous PAX5 and the specific transcription profile are responsible for aberrant mechanisms essential in the leukemic transformation (Supplementary Figure S5) . First, PAX5/ETV6 determines a PAX5 haplo-insufficiency setting; second, the PAX5/ETV6 fusion protein could be actively responsible for the B-cell development block, mediated by the repression of physiological PAX5-activated genes. Moreover, the fusion protein may induce the acquisition of novel features, due to the aberrant upregulation of genes that are normally repressed in precursor B cells. It will be crucial to confirm these phenomena and understand the molecular mechanisms of the opposite dominant function in in vivo mouse models and in primary patients' cells carrying PAX5 translocations.
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